<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries. In: Guidelines for the management of acute cervical spine and spinal cord injuries.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dhall SS, Hadley MN, Aarabi B, Gelb DE, Hurlbert RJ, Rozzelle CJ, Ryken TC, Theodore N, Walters BC. Deep venous thrombosis and thromboembolism in patients with cervical spinal cord  injuries. In: Guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery. 2013 Mar;72(Suppl 2):244-54. [57 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23417195&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The rating schemes used for the strength of the evidence (&lt;strong&gt;Class I-III&lt;/strong&gt;) and the levels of recommendations (&lt;strong&gt;Level I-III&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prophylaxis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Level I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prophylactic treatment of venous thromboembolism (VTE) in patients with severe motor deficits due to spinal cord injury (SCI) is recommended. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of low molecular weight heparins (LMWHs), rotating beds, or a combination of modalities is recommended as a prophylactic treatment strategy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low dose heparin in combination with pneumatic compression stockings or electrical stimulation is recommended as a prophylactic treatment strategy. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Level II&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Low dose heparin therapy alone is not recommended as a prophylactic treatment strategy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oral anticoagulation alone is not recommended as a prophylactic treatment strategy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Early administration of VTE prophylaxis (within 72 hours) is recommended. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A 3-month duration of prophylactic treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE) is recommended. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Level III&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Vena cava filters are not recommended as a routine prophylactic measure, but are recommended for select patients who fail anticoagulation or who are not candidates for anticoagulation and/or mechanical devices. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Level III&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Duplex Doppler ultrasound, impedance plethysmography, venous occlusion plethysmography, venography, and the clinical examination are recommended for use as diagnostic tests for DVT in the spinal cord-injured population. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Summary&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Thromboembolic disease is a common occurrence in patients who have sustained a cervical spinal cord injury and is associated with significant morbidity. &lt;strong&gt;Class I&lt;/strong&gt; medical evidence exists demonstrating the efficacy of several means of prophylaxis for the prevention of thromboembolic events. Therefore, patients with SCI should be treated with a regimen aimed at VTE prophylaxis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although low dose heparin therapy has been reported to be effective as prophylaxis for thromboembolism in several &lt;strong&gt;Class III&lt;/strong&gt; studies, other &lt;strong&gt;Class I, Class II&lt;/strong&gt;, and &lt;strong&gt;Class III&lt;/strong&gt; medical evidence indicates that better alternatives than low dose heparin therapy exist. These alternatives include the use of LMWH, adjusted dose heparin, or anticoagulation in conjunction with rotating beds, pneumatic compression devices or electrical stimulation. Oral anticoagulation alone does not appear to be as effective as these other measures used for prophylaxis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There appears to be a DVT prophylaxis benefit to early anticoagulation in acute SCI patients. &lt;strong&gt;Class II&lt;/strong&gt; medical evidence supports beginning mechanical and chemical prophylaxis upon admission after SCI and holding chemical prophylaxis 1 day prior to and 1 day following surgical intervention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The incidence of thromboembolic events appears to decrease over time and the prolonged use of anticoagulant therapy is associated with a definite incidence of bleeding complications. There are multiple reports of the beneficial effects of the prophylaxis therapy for 6 to 12 weeks following SCI. &lt;strong&gt;Class II&lt;/strong&gt; medical evidence indicates that the majority of thromboembolic events occur in the first 3 months following acute SCI and very few occur thereafter. For these reasons, it is recommended that prophylactic therapy be discontinued after 3 months unless the patient is at high risk for a future VTE event (previous thromboembolic events, obesity, advanced age). It is reasonable to discontinue therapy earlier in patients with retained lower extremity motor function after SCI, as the incidence of thromboembolic events in these patients is substantially lower than among those patients with motor complete injuries.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although the guidelines author group concluded that caval filters appeared to be efficacious for the prevention of PE in SCI patients in the 2002 guideline on this topic, more recent medical evidence suggests that prophylactic filters may be more morbid than initially believed. Caval filters still have a role for SCI patients who have suffered thromboembolic events despite anticoagulation, and for SCI patients with contraindications to anticoagulation and/or the use of pneumatic compression devices.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There are several methods available for the diagnosis of DVT. Venography has long been considered the best test, but is invasive, not applicable to all patients, and is associated with intrinsic morbidity. Duplex Doppler ultrasound, impedance plethysmography, venous occlusion plethysmography and the clinical examination have been reported to have sensitivities of approximately 90% and are noninvasive. It is recommended that these noninvasive tests be used for the diagnosis of DVT in SCI patients and that venography to diagnose DVT be reserved for the rare situation when clinical suspicion is high and the results of ultrasound or plethysmography testing are negative.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rating Scheme for the Strength of the Evidence: Modified North American Spine Society Schema to Conform to Neurosurgical Criteria as Previously Published and for Ease of Understanding and Implementation: Levels of Evidence for Primary Research Question&lt;sup&gt;a&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Rating Scheme for the Strength of the Evidence: Modified North American Spine Society Schema to Conform to Neurosurgical Criteria as Previously Published and for Ease of Understanding and Implementation: Levels of Evidence for Primary Research Question&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Therapeutic Studies: Investigating the Results of Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Diagnostic Studies: Investigating a Diagnostic Test&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Clinical Assessment: Studies of Reliability and Validity of Observations, Including Clinical Examination, Imaging Results, and Classifications&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-quality randomized controlled trial with statistically significant difference or no statistically significant difference but narrow confidence intervals&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence provided by 1 or more well-designed clinical studies in which interobserver and intraobserver reliability is represented by a Ä¸ statistic &amp;ge;0.60 or an intraclass correlation coefficient of &amp;ge;0.70&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class I randomized controlled trials (and study results were homogeneous&lt;sup&gt;c&lt;/sup&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class I studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;6&quot;&gt;II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lesser-quality randomized controlled trial (e.g., &amp;lt;80% follow-up, no blinding, or improper randomization)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Development of diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence provided by 1 or more well-designed clinical studies in which interobserver and intraobserver reliability is represented by a Ä¸ statistic of 0.40&amp;ndash;0.60 or an intraclass correlation coefficient of 0.50&amp;ndash;0.70&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Prospective&lt;sup&gt;d&lt;/sup&gt; comparative study&lt;sup&gt;e&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class II studies or Class I studies with inconsistent results&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Study of nonconsecutive patients; without consistently applied reference &quot;gold&quot; standard&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control study&lt;sup&gt;g&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class III studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Retrospective&lt;sup&gt;f&lt;/sup&gt; comparative study&lt;sup&gt;e&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;III&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series&lt;sup&gt;h&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Poor reference standard&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence provided by 1 or more well-designed clinical studies in which interobserver and intraobserver reliability is represented by a Ä¸ statistic of &amp;lt;0.40 or an intraclass correlation coefficient of &amp;lt;0.50&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;A combination of results from 2 or more prior studies.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;c&lt;/sup&gt;Studies provided consistent results.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;d&lt;/sup&gt;Study was started before the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;e&lt;/sup&gt;Patients treated 1 way (e.g., halo vest orthosis) compared with a group of patients treated in another way (e.g., internal fixation) at the same institution.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;f&lt;/sup&gt;The study was started after the first patient was enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;g&lt;/sup&gt;Patients identified for the study on the basis of their outcome, called &quot;cases&quot; (e.g., failed fusion), are compared with those who did not have outcome, called &quot;controls&quot; (e.g., successful fusion).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;h&lt;/sup&gt;Patients treated 1 way with no comparison group of patients treated in another way.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Generally accepted principles for patient management, which reflect a high degree of clinical certainty (usually this requires Class I evidence which directly addresses the clinical questions or overwhelming Class II evidence when circumstances preclude randomized clinical trials)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations for patient management which reflect moderate clinical certainty (usually this requires Class II evidence or a strong consensus of Class III evidence)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level III&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other strategies for patient management for which the clinical utility is uncertain (inconclusive or conflicting evidence or opinion)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Deep venous thrombosis and thromboembolism following acute cervical spinal cord injury&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Diagnosis" />
      <FieldValue Value="Management" />
      <FieldValue Value="Prevention" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Hematology" />
      <FieldValue Value="Neurological Surgery" />
      <FieldValue Value="Neurology" />
      <FieldValue Value="Orthopedic Surgery" />
      <FieldValue Value="Radiology" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Advanced Practice Nurses" />
      <FieldValue Value="Hospitals" />
      <FieldValue Value="Nurses" />
      <FieldValue Value="Physician Assistants" />
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To update, evaluate, and rank the literature on the methods of prevention, identification, and treatment of venous thromboembolism (VTE) complications in patients following acute cervical spinal cord injury (SCI) published since 2002&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients who have sustained cervical spinal cord injuries (SCIs) at risk for deep venous thrombosis (DVT) and thromboembolism&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Duplex Doppler ultrasound &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Impedance plethysmography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Venous occlusion plethysmography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Venography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical examination &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prevention/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Low-molecular-weight heparins &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rotating beds &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low-dose heparin combined with pneumatic compression stockings or electrical stimulation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Early administration of venous thromboembolism (VTE) prophylaxis (within 72 hours) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Three-month duration of prophylactic therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vena cava filters (for select patients only) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combination of modalities &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Low-dose heparin alone and oral anticoagulation alone were considered but not recommended for prophylaxis.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk of deep vein thrombosis (DVT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of DVT and pulmonary embolism (PE) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests for DVT &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of prophylactic interventions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness of prophylactic interventions &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Search Criteria&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;A National Library of Medicine (PubMed) computerized literature search from 1966 through 2011 was performed using Medical Subject Headings in combination with &quot;spinal cord injury&quot;: &quot;deep venous thrombosis,&quot; &quot;pulmonary embolism,&quot; and &quot;thromboembolism.&quot; The search was limited to human studies reported in the English language. This resulted in 599 citations. Duplicate references, reviews, letters, and tangential reports were discarded. The bibliographies of these citations were analyzed for additional potential contributions. Finally, the author group found 45 citations describing the diagnosis, prophylaxis or treatment of thromboembolic disease in adult spinal cord injured patients make up the basis for this guideline. Supporting references included 4 evidence-based reviews on venous thromboembolism (VTE) prophylaxis and treatment in a variety of patient populations. Finally, several series dealing with VTE in general trauma patients with results germane to a discussion of spinal cord injured patients are included in the bibliography as supporting documents.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Forty-five citations describing the diagnosis, prophylaxis or treatment of thromboembolic disease in adult spinal cord injured patients make up the basis for this guideline and are summarized in Evidentiary Table format (see the table in the original guideline document).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Rating Scheme for the Strength of the Evidence: Modified North American Spine Society Schema to Conform to Neurosurgical Criteria as Previously Published and for Ease of Understanding and Implementation: Levels of Evidence for Primary Research Question&lt;sup&gt;a&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Rating Scheme for the Strength of the Evidence: Modified North American Spine Society Schema to Conform to Neurosurgical Criteria as Previously Published and for Ease of Understanding and Implementation: Levels of Evidence for Primary Research Question&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Therapeutic Studies: Investigating the Results of Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Diagnostic Studies: Investigating a Diagnostic Test&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Clinical Assessment: Studies of Reliability and Validity of Observations, Including Clinical Examination, Imaging Results, and Classifications&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-quality randomized controlled trial with statistically significant difference or no statistically significant difference but narrow confidence intervals&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence provided by 1 or more well-designed clinical studies in which interobserver and intraobserver reliability is represented by a Ä¸ statistic &amp;ge;0.60 or an intraclass correlation coefficient of &amp;ge;0.70&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class I randomized controlled trials (and study results were homogeneous&lt;sup&gt;c&lt;/sup&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class I studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;6&quot;&gt;II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lesser-quality randomized controlled trial (e.g., &amp;lt;80% follow-up, no blinding, or improper randomization)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Development of diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence provided by 1 or more well-designed clinical studies in which interobserver and intraobserver reliability is represented by a Ä¸ statistic of 0.40&amp;ndash;0.60 or an intraclass correlation coefficient of 0.50&amp;ndash;0.70&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Prospective&lt;sup&gt;d&lt;/sup&gt; comparative study&lt;sup&gt;e&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class II studies or Class I studies with inconsistent results&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Study of nonconsecutive patients; without consistently applied reference &quot;gold&quot; standard&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control study&lt;sup&gt;g&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class III studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Retrospective&lt;sup&gt;f&lt;/sup&gt; comparative study&lt;sup&gt;e&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;sup&gt;b&lt;/sup&gt; of Class II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;III&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series&lt;sup&gt;h&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Poor reference standard&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence provided by 1 or more well-designed clinical studies in which interobserver and intraobserver reliability is represented by a Ä¸ statistic of &amp;lt;0.40 or an intraclass correlation coefficient of &amp;lt;0.50&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;A combination of results from 2 or more prior studies.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;c&lt;/sup&gt;Studies provided consistent results.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;d&lt;/sup&gt;Study was started before the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;e&lt;/sup&gt;Patients treated 1 way (e.g., halo vest orthosis) compared with a group of patients treated in another way (e.g., internal fixation) at the same institution.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;f&lt;/sup&gt;The study was started after the first patient was enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;g&lt;/sup&gt;Patients identified for the study on the basis of their outcome, called &quot;cases&quot; (e.g., failed fusion), are compared with those who did not have outcome, called &quot;controls&quot; (e.g., successful fusion).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;h&lt;/sup&gt;Patients treated 1 way with no comparison group of patients treated in another way.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Selected articles were carefully reviewed by the authors. An evidentiary table was created (refer to the table in the original guideline document) that reflected the strengths and weaknesses of each article.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;On occasion, the assessed quality of the study design was so contentious and the conclusions so uncertain that the guideline authors assigned a lower medical evidence classification than might have been expected without such a detailed review. In every way, adherence to the Institute of Medicine's criteria for searching, assembling, evaluating, and weighing the available medical evidence and linking it to the strength of the recommendations presented in this document was carried out.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Articles that did not achieve immediate consensus among the author group were discussed extensively until a consensus was reached. Very few contributions required extensive discussion. Most articles were easily designated as containing Class I, II, or III medical evidence using the criteria set forth by the author group at the initiation of the literature evaluation process (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The current author group was selected for its expertise in spinal surgery (both neurosurgical and orthopedic), neurotrauma, clinical epidemiology, and, in several cases, prior experience with guideline development. The topics chosen for inclusion in this iteration of these guidelines are contemporary and pertinent to the assessment, evaluation, care, and treatment of patients with acute cervical spine and/or spinal cord injuries.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Generally accepted principles for patient management, which reflect a high degree of clinical certainty (usually this requires Class I evidence which directly addresses the clinical questions or overwhelming Class II evidence when circumstances preclude randomized clinical trials)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations for patient management which reflect moderate clinical certainty (usually this requires Class II evidence or a strong consensus of Class III evidence)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level III&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other strategies for patient management for which the clinical utility is uncertain (inconclusive or conflicting evidence or opinion)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed a published cost analysis.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="Not stated" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Accurate diagnosis and prevention of deep venous thrombosis (DVT) and thromboembolism&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prolonged prophylactic anticoagulation therapy is not without risk, and is associated with bleeding complications. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The placement of inferior vena cava (IVC) filters is not without complications. Several authors have described distal migration, intraperitoneal erosion, and symptomatic IVC occlusion in patients with spinal cord injuries (SCIs) treated with IVC filters. One group of researchers has hypothesized that quadriplegic patients are at higher risk for complications from IVC filter placement due to loss of abdominal muscle tone, as well as their requisite use of the &quot;quad cough&quot; maneuver. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Venography has been considered the best test for diagnosis of deep vein thrombosis (DVT), but is too inaccurate, is not possible in all patients, is invasive, and expensive. A 10% incidence of adverse effects from venography including post-venographic phlebitis and allergic reactions has been reported. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Medical evidence-based guidelines are not meant to be restrictive or to limit a clinician's practice. They chronicle multiple successful treatment options (for example) and stratify the more successful and the less successful strategies based on scientific merit. They are not absolute, &quot;must be followed&quot; rules. This process may identify the most valid and reliable imaging strategy for a given injury, for example, but because of regional or institutional resources, or patient co-morbidity, that particular imaging strategy may not be possible for a patient with that injury. Alternative acceptable imaging options may be more practical or applicable in this hypothetical circumstance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Guidelines documents are not tools to be used by external agencies to measure or control the care provided by clinicians. They are not medical-legal instruments or a &quot;set of certainties&quot; that must be followed in the assessment or treatment of the individual pathology in the individual patients we treat. While a powerful and comprehensive resource tool, guidelines and the recommendations contained therein do not necessarily represent &quot;the answer&quot; for the medical and surgical dilemmas faced with many patients. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many">
      <FieldValue Value="Mobile Device Resources" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
      <FieldValue Value="Staying Healthy" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dhall SS, Hadley MN, Aarabi B, Gelb DE, Hurlbert RJ, Rozzelle CJ, Ryken TC, Theodore N, Walters BC. Deep venous thrombosis and thromboembolism in patients with cervical spinal cord  injuries. In: Guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery. 2013 Mar;72(Suppl 2):244-54. [57 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23417195&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2013 Mar" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="American Association of Neurological Surgeons - Medical Specialty Society" />
      <FieldValue Value="Congress of Neurological Surgeons - Professional Association" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Congress of Neurological Surgeons&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guidelines Author Group of the Joint Section of Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Sanjay S. Dhall, MD, Department of Neurosurgery, Emory University, Atlanta, Georgia; Mark N. Hadley, MD (&lt;em&gt;Lead Author&lt;/em&gt;), Division of Neurological Surgery, University of Alabama at Birmingham, Birmingham, Alabama; Bizhan Aarabi, MD, FRCSC, Department of Neurosurgery, University of Maryland, Baltimore, Maryland; Daniel E. Gelb, MD, Department of Orthopaedics, University of Maryland, Baltimore, Maryland; R. John Hurlbert, MD, PhD, FRCSC, Department of Clinical Neurosciences, University of Calgary Spine Program, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; Curtis J. Rozzelle, MD, Division of Neurological Surgery, Children's Hospital of Alabama, University of Alabama at Birmingham, Birmingham, Alabama; Timothy C. Ryken, MD, MS, Iowa Spine &amp;amp; Brain Institute, University of Iowa, Waterloo/Iowa City, Iowa; Nicholas Theodore, MD, Division of Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona; Beverly C. Walters, MD, MSc, FRCSC (&lt;em&gt;Lead Author&lt;/em&gt;), Division of Neurological Surgery, University of Alabama at Birmingham, Birmingham, Alabama, Department of Neurosciences, Inova Health System, Falls Church, Virginia&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;http://journals.lww.com/neurosurgery/Fulltext/2013/03002/Deep_Venous_Thrombosis_and_Thromboembolism_in.25.aspx&quot; title=&quot;Neurosurgery Web site&quot;&gt;Neurosurgery Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Foreword. Guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery 2013;72(3):1. Available from the &lt;a href=&quot;http://journals.lww.com/neurosurgery/Fulltext/2013/03002/Foreword.1.aspx&quot; title=&quot;Neurosurgery Web site&quot;&gt;Neurosurgery Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Commentary. Guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery 2013;72(3):2-3. Available from the &lt;a href=&quot;http://journals.lww.com/neurosurgery/Fulltext/2013/03002/Commentary.2.aspx&quot; title=&quot;Neurosurgery Web site&quot;&gt;Neurosurgery Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Introduction to the guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery 2013;72(3):5-16. Available from the &lt;a href=&quot;http://journals.lww.com/neurosurgery/Fulltext/2013/03002/Introduction_to_the_Guidelines_for_the_Management.4.aspx&quot; tilte=&quot;Neurosurgery Web site&quot;&gt;Neurosurgery Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Methodology of the guidelines for management of acute cervical spine and spinal cord injuries. Neurosurgery 2013;72(3):17-21. Available from the &lt;a href=&quot;http://journals.lww.com/neurosurgery/Fulltext/2013/03002/Methodology_of_the_Guidelines_for_the_Management.5.aspx&quot; title=&quot;Neurosurgery Web site&quot;&gt;Neurosurgery Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on July 9, 2013. The information was verified by the guideline developer on October 3, 2013. This summary was updated by ECRI Institute on March 10, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>